The researchers found that new-onset AF correlated with increased risk of heart failure in multivariable models.
Earlier treatment remained significantly correlated with lower in-hospital mortality in multivariate analysis.
CKD patients treated to a target systolic blood pressure of less than 120 mm Hg were 28% less likely to die early.
Combining quarter doses of two drugs was as effective as a single standard dose of one blood pressure-lowering medication.
The researchers observed linear associations between mean achieved SBP and risk of cardiovascular disease and mortality.
Compared with individuals reporting chocolate intake less than once per month, the rate of AF was lower for people consuming chocolate regularly.
Dietary sodium intake guidelines may be misguided.
A total of 16 men had received an LVAD and then had it removed because they had significant recovery of heart function.
The risk of major bleeding is similar for older patients with atrial fibrillation taking either antiplatelet or anticoagulant drugs.
As 25(OH)D levels increased, systolic blood pressure decreased significantly, even after accounting for calcium intake.
A majority of sodium consumed was from food obtained at stores; however, sodium density was highest in food obtained at restaurants.
The majority of the ischemic cardiomyopathy patients showed improvement in pulmonary artery pressure, pulmonary capillary wedge pressure, pulmonary vein resistance, and left ventricular wall stress.
MRI measurements reflecting RV structure and stiffness of the proximal pulmonary vasculature are independent predictors of outcome in PAH.
Overall, patients on omega-3 supplements had an 8% lower risk of total mortality or hospitalization for cardiovascular disease over 4 years.
Study documents higher risks even when creatinine increases are less than 30%, the guideline-recommended threshold for stopping treatment.
Blood pressure targets below 130/80 and below 140/90 mm Hg are associated with similar renal outcomes among non-diabetics, meta-analysis shows.
People with high blood pressure consumed an average of 2,900 mg of sodium per day in 1999 and 3350 mg per day in 2012, for an overall average daily sodium intake of 3100 mg.
Changes over time in prescription adherence are common and affect treatment estimates considerably.
Numerous population studies demonstrate a relationship between higher dietary K+ and lower blood pressure regardless of sodium intake.
Among the etiologies of readmission, cardiac causes including heart failure and coronary artery disease were most common.
With dietitian counseling, limiting sodium to 2000 mg per daily is feasible for chronic kidney disease patients.
Adjusted rates of hospitalization for AF increased by almost 1% per year between 1999 and 2013.
In the United States, more than 92.1 million people have cardiovascular disease.
An estimated 12.3% of Americans over the age of 21 have masked hypertension.
New guidelines suggest aiming for a systolic pressure less than 150 mm Hg in hypertensive individuals aged 60 or older.
With respect to mortality and hospitalizations, there were no significant interactions for β-blockers and pattern or burden of AF.
To receive top ratings, a diet has to be relatively easy to follow, nutritious, safe, effective for weight loss, and protective against diabetes and heart disease.
United States, China, India, Indonesia, and Russia accounted for more than 50% of elevated or high blood pressure cases.
Clinically important heterogeneity in intensive BP treatment remains undetectable in conventional trial designs but can be detected in sequential randomization trial designs.
Spironolactone use was associated with 12% decreased odds of prostate cancer in male patients and 19% decreased odds of bladder cancer in female patients.
Renal and Urology News Articles
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)